Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

QKI-V5 is downregulated in CNS inflammatory demyelinating diseases.

Lavon I, Leykin I, Charbit H, Binyamin O, Brill L, Ovadia H, Vaknin-Dembinsky A.

Mult Scler Relat Disord. 2019 Dec 4;39:101881. doi: 10.1016/j.msard.2019.101881. [Epub ahead of print]

PMID:
31835207
2.

MIF -173G/C polymorphism is associated with NMO disease severity.

Brill L, Vaknin-Dembinsky A, Zveik O, Haham N, Miller K, Benedek G.

J Neuroimmunol. 2020 Feb 15;339:577120. doi: 10.1016/j.jneuroim.2019.577120. Epub 2019 Nov 25.

PMID:
31790982
3.

MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine.

Cavalcante P, Mizrachi T, Barzago C, Scandiffio L, Bortone F, Bonanno S, Frangiamore R, Mantegazza R, Bernasconi P, Brenner T, Vaknin-Dembinsky A, Antozzi C.

Pharmacol Res. 2019 Oct;148:104388. doi: 10.1016/j.phrs.2019.104388. Epub 2019 Aug 8.

PMID:
31401213
4.

[AUTOIMMUNE ENCEPHALITIS: A BRIDGE BETWEEN NEUROLOGY AND PSYCHIATRY].

Benoliel T, Ben-Hur T, Vaknin-Dembinsky A.

Harefuah. 2019 Jun;158(6):361-366. Hebrew.

PMID:
31215187
5.

Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.

Lavon I, Heli C, Brill L, Charbit H, Vaknin-Dembinsky A.

Front Immunol. 2019 Apr 30;10:835. doi: 10.3389/fimmu.2019.00835. eCollection 2019.

6.

Corrigendum to "Foxp3+ regulatory T cells expression in Neuromyelitis optica spectrum disorders" [Multiple Sclerosis and Related Disorders 30 (2019) 114-118].

Brill L, Lavon I, Vaknin-Dembinsky A.

Mult Scler Relat Disord. 2019 May;30:291. doi: 10.1016/j.msard.2019.02.024. Epub 2019 Mar 23. No abstract available.

PMID:
30987752
7.

Foxp3+ regulatory T cells expression in neuromyelitis optica spectrum disorders.

Brill L, Lavon I, Vaknin-Dembinsky A.

Mult Scler Relat Disord. 2019 May;30:114-118. doi: 10.1016/j.msard.2019.01.047. Epub 2019 Jan 30. Erratum in: Mult Scler Relat Disord. 2019 May;30:291.

PMID:
30771576
8.

Reduced expression of the IL7Ra signaling pathway in Neuromyelitis optica.

Brill L, Lavon I, Vaknin-Dembinsky A.

J Neuroimmunol. 2018 Nov 15;324:81-89. doi: 10.1016/j.jneuroim.2018.08.011. Epub 2018 Aug 29.

PMID:
30248528
9.

NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.

Mizrachi T, Brill L, Rabie M, Nevo Y, Fellig Y, Zur M, Karussis D, Abramsky O, Brenner T, Vaknin-Dembinsky A.

J Immunol Res. 2018 May 22;2018:5389282. doi: 10.1155/2018/5389282. eCollection 2018.

10.

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).

Vaknin-Dembinsky A, Charbit H, Brill L, Abramsky O, Gur-Wahnon D, Ben-Dov IZ, Lavon I.

J Neuroinflammation. 2016 Jul 8;13(1):179. doi: 10.1186/s12974-016-0648-x.

11.

T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO).

Vaknin-Dembinsky A, Brill L, Kassis I, Petrou P, Ovadia H, Ben-Hur T, Abramsky O, Karussis D.

Mult Scler Relat Disord. 2016 Mar;6:28-36. doi: 10.1016/j.msard.2015.12.004. Epub 2015 Dec 11.

PMID:
27063619
12.

Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel.

Brill L, Mandel M, Karussis D, Petrou P, Miller K, Ben-Hur T, Karni A, Paltiel O, Israel S, Vaknin-Dembinsky A.

J Neuroimmunol. 2016 Apr 15;293:65-70. doi: 10.1016/j.jneuroim.2016.02.006. Epub 2016 Feb 15.

PMID:
27049564
13.

Identification of tissue-specific cell death using methylation patterns of circulating DNA.

Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Hubert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1826-34. doi: 10.1073/pnas.1519286113. Epub 2016 Mar 14.

14.

Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-β.

Mausner-Fainberg K, Kolb H, Penn M, Regev K, Vaknin-Dembinsky A, Gadoth A, Kestenbaum M, Karni A.

J Neuroimmunol. 2016 Mar 15;292:93-6. doi: 10.1016/j.jneuroim.2016.01.019. Epub 2016 Jan 30.

PMID:
26943965
15.

Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.

Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D.

JAMA Neurol. 2016 Mar;73(3):337-44. doi: 10.1001/jamaneurol.2015.4321.

PMID:
26751635
16.

Effectiveness of multi-disciplinary rehabilitation for patients with Neuromyelitis Optica.

Nechemia Y, Moreh E, Weingarden H, Bloch A, Givon U, Vaknin-Dembinsky A, Schwartz I, Meiner Z, Zeilig G.

J Spinal Cord Med. 2016 May;39(3):311-6. doi: 10.1179/2045772315Y.0000000060. Epub 2016 Mar 24.

17.

Increased neutralization capacity of TNF-α in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-α receptors or anti-TNF-α autoantibody levels.

Mausner-Fainberg K, Regev K, Kolb H, Vaknin-Dembinsky A, Karni A.

J Neuroimmunol. 2015 Sep 15;286:83-5. doi: 10.1016/j.jneuroim.2015.07.005. Epub 2015 Jul 17.

PMID:
26298329
18.

Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis.

Charbit H, Benis A, Geyshis B, Karussis D, Petrou P, Vaknin-Dembinsky A, Lavon I.

J Clin Neurosci. 2015 Jun;22(6):986-9. doi: 10.1016/j.jocn.2014.11.027. Epub 2015 Apr 14.

PMID:
25882258
19.

Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients.

Levy YA, Mausner-Fainberg K, Vaknin-Dembinsky A, Amidror T, Regev K, Karni A.

J Neuroimmunol. 2015 Jan 15;278:85-9. doi: 10.1016/j.jneuroim.2014.12.010. Epub 2014 Dec 10.

PMID:
25595256
20.

Tumefactive demyelination following in vitro fertilization (IVF).

Vaknin-Dembinsky A, Bdolah Y, Karussis D, Rosenthal G, Petrou P, Fellig Y, Abramsky O, Lossos A.

J Neurol Sci. 2015 Jan 15;348(1-2):256-8. doi: 10.1016/j.jns.2014.11.016. Epub 2014 Nov 18.

PMID:
25499758
21.

Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?

Brill L, Goldberg L, Karni A, Petrou P, Abramsky O, Ovadia H, Ben-Hur T, Karussis D, Vaknin-Dembinsky A.

Mult Scler. 2015 Apr;21(5):572-9. doi: 10.1177/1352458514551779. Epub 2014 Nov 12.

PMID:
25392324
22.

NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases.

Vaknin-Dembinsky A, Karussis D, Avichzer J, Abramsky O.

J Autoimmun. 2014 Nov;54:93-9. doi: 10.1016/j.jaut.2014.05.004. Epub 2014 Aug 14. Review.

PMID:
25129503
23.

Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy.

Petrou P, Argov A, Lennon VA, Gotkine M, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D.

Muscle Nerve. 2014 Mar;49(3):455-7. doi: 10.1002/mus.24143. Epub 2014 Jan 20. No abstract available.

PMID:
24327321
24.

[Inflammation of the optic nerve: when it should be considered as neuromyelitis optica--the experience of the Department of Neurology at Hadassah Hospital].

Vaknin-Dembinsky A, Levin N, Raz N, Abramsky O, Karussis D, Brill L, Petrou P, Ovadia H.

Harefuah. 2013 Feb;152(2):101-5, 122. Hebrew.

PMID:
23513502
25.

Central nervous system vasculitis.

Gotkine M, Vaknin-Dembinsky A.

Curr Treat Options Neurol. 2013 Jun;15(3):367-74. doi: 10.1007/s11940-013-0227-8.

PMID:
23475760
26.

T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Karussis D, Shor H, Yachnin J, Lanxner N, Amiel M, Baruch K, Keren-Zur Y, Haviv O, Filippi M, Petrou P, Hajag S, Vourka-Karussis U, Vaknin-Dembinsky A, Khoury S, Abramsky O, Atlan H, Cohen IR, Abulafia-Lapid R.

PLoS One. 2012;7(12):e50478. doi: 10.1371/journal.pone.0050478. Epub 2012 Dec 14.

27.

T-cell reactivity against AQP4 in neuromyelitis optica.

Vaknin-Dembinsky A, Brill L, Kassis I, Petrou P, Ovadia H, Ben-Hur T, Abramsky O, Karussis D.

Neurology. 2012 Aug 28;79(9):945-6. doi: 10.1212/WNL.0b013e318266fc2b. Epub 2012 Aug 15. No abstract available.

PMID:
22895587
28.

Pediatric demyelinating diseases: multiple sclerosis or not?

Vaknin-Dembinsky A, Karussis D.

Isr Med Assoc J. 2012 Apr;14(4):251-3. No abstract available.

29.

Neurologic manifestations of systemic immunopathological diseases.

Gotkine M, Vaknin-Dembinsky A.

Curr Treat Options Neurol. 2012 Jun;14(3):276-92. doi: 10.1007/s11940-012-0171-z.

PMID:
22399412
30.

Robot-assisted gait training in multiple sclerosis patients: a randomized trial.

Schwartz I, Sajin A, Moreh E, Fisher I, Neeb M, Forest A, Vaknin-Dembinsky A, Karusis D, Meiner Z.

Mult Scler. 2012 Jun;18(6):881-90. doi: 10.1177/1352458511431075. Epub 2011 Dec 6.

PMID:
22146609
31.

Pseudo-quadriceps sparing in multiple sclerosis.

Levin N, Vaknin-Dembinsky A, Petrou P, Grigoriadis N, Deretzi G, Karussis D.

Eur J Neurol. 2011 Sep;18(9):1184-6. doi: 10.1111/j.1468-1331.2010.03331.x. Epub 2011 Feb 8.

PMID:
21834903
32.

Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle?

Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, Brill L, Brenner T, Argov Z, Karussis D.

Arch Neurol. 2011 Dec;68(12):1557-61. doi: 10.1001/archneurol.2011.200. Epub 2011 Aug 8.

PMID:
21825214
33.

Limbic encephalitis presenting as a post-partum psychiatric condition.

Gotkine M, Ben-Hur T, Vincent A, Vaknin-Dembinsky A.

J Neurol Sci. 2011 Sep 15;308(1-2):152-4. doi: 10.1016/j.jns.2011.06.017. Epub 2011 Jun 25.

PMID:
21705029
34.

Response to letter from Dr Hongliang Zhang entitled 'B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica and multiple sclerosis'.

Vaknin-Dembinsky A, Karussis D.

Mult Scler. 2011 May;17(5):641. doi: 10.1177/1352458511400230. No abstract available.

PMID:
28071242
35.

Familial Mediterranean fever (FMF) and multiple sclerosis: an association study in one of the world's largest FMF cohorts.

Yahalom G, Kivity S, Lidar M, Vaknin-Dembinsky A, Karussis D, Flechter S, Ben-Chetrit E, Livneh A.

Eur J Neurol. 2011 Sep;18(9):1146-50. doi: 10.1111/j.1468-1331.2011.03356.x. Epub 2011 Feb 8.

PMID:
21299735
36.

Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis.

Balashov KE, Aung LL, Vaknin-Dembinsky A, Dhib-Jalbut S, Weiner HL.

Ann Neurol. 2010 Dec;68(6):899-906. doi: 10.1002/ana.22136.

37.

Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection.

Kassis I, Vaknin-Dembinsky A, Karussis D.

Curr Stem Cell Res Ther. 2011 Mar;6(1):63-8. Review.

PMID:
20955154
38.

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S.

Arch Neurol. 2010 Oct;67(10):1187-94. doi: 10.1001/archneurol.2010.248.

39.

Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population.

Vaknin-Dembinsky A, Brill L, Orpaz N, Abramsky O, Karussis D.

Mult Scler. 2010 Dec;16(12):1453-7. doi: 10.1177/1352458510380416. Epub 2010 Oct 8.

PMID:
20935029
40.

Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting.

Karussis D, Vaknin-Dembinsky A.

Expert Rev Clin Immunol. 2010 May;6(3):347-52. doi: 10.1586/eci.10.7.

PMID:
20441420
41.
42.

Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis.

Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, Astier AL, Weiner HL.

J Neuroimmunol. 2008 Mar;195(1-2):140-5. doi: 10.1016/j.jneuroim.2008.01.002. Epub 2008 Apr 10.

43.

Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS.

Vaknin-Dembinsky A, Brass SD, Gandhi R, Weiner HL.

J Neuroimmunol. 2008 Mar;195(1-2):135-9. doi: 10.1016/j.jneuroim.2008.01.016. Epub 2008 Apr 1. Erratum in: J Neuroimmunol. 2009 Feb 15;207(1-2):122. Brass, Steven [corrected to Brass, Steven D].

44.

Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.

Vaknin-Dembinsky A, Weiner HL.

J Neurol Sci. 2007 Aug 15;259(1-2):90-4. Epub 2007 May 23. Review.

PMID:
17521671
45.

IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production.

Vaknin-Dembinsky A, Balashov K, Weiner HL.

J Immunol. 2006 Jun 15;176(12):7768-74. Erratum in: J Immunol. 2006 Aug 1;177(3):2025.

46.

Neurological deficits in patients with celiac disease.

Vaknin-Dembinsky A, Eliakim R, Steiner I.

Arch Neurol. 2002 Apr;59(4):647-8. No abstract available.

PMID:
11939904

Supplemental Content

Loading ...
Support Center